What is the best way to manage lithium-induced hyperparathyroidism (Hyperparathyroidism caused by lithium, a medication used to treat bipolar disorder)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Article Review Status
Submitted
Under Review
Approved

Last updated: March 17, 2025 • View editorial policy

From the Research

The best approach to manage lithium-induced hyperparathyroidism is a multifaceted one, prioritizing regular monitoring of serum calcium, parathyroid hormone (PTH), and vitamin D levels, and considering surgical intervention with parathyroidectomy for severe or refractory cases, as supported by the most recent study 1.

Key Considerations

  • Regular monitoring of serum calcium, PTH, and vitamin D levels is essential for early detection and management of lithium-induced hyperparathyroidism.
  • For mild cases, conservative management includes adequate hydration and dietary calcium moderation.
  • Pharmacological options, such as cinacalcet, may be considered for reducing PTH secretion.
  • Surgical intervention with parathyroidectomy may be required for severe or refractory cases, particularly with significant hypercalcemia, kidney stones, or bone disease.

Surgical Approach

  • The most recent study 1 suggests that minimally invasive parathyroidectomy (MIP) may be the optimum surgical approach for lithium-associated hyperparathyroidism.
  • However, bilateral exploration may be necessary in some cases to minimize the risk of disease recurrence, as noted in study 2.

Collaboration and Monitoring

  • Close collaboration between psychiatrists, endocrinologists, and potentially surgeons is crucial for optimal management of lithium-induced hyperparathyroidism while maintaining psychiatric stability.
  • Regular monitoring of patients with lithium-induced hyperparathyroidism is essential to prevent long-term complications and ensure timely intervention when necessary, as emphasized in study 3.

Underlying Mechanism

  • The underlying mechanism of lithium-induced hyperparathyroidism involves lithium's interference with calcium-sensing receptors, leading to increased PTH secretion and subsequent hypercalcemia, as discussed in study 4.

References

Research

Lithium-Associated Hyperparathyroidism: A Pooled Analysis.

ORL; journal for oto-rhino-laryngology and its related specialties, 2015

Research

Reversible hypercalcemia and hyperparathyroidism associated with lithium therapy: case report and review of literature.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2006

Research

[Hyperparathyroidism with lithium].

L'Encephale, 1994

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.